Xenetic Biosciences (XBIO) Stock Price, News & Analysis

Company Overview

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Key Stats

• Today's Range: $3.52 to $4.09
• 50-Day Range: $2.69 to $3.99
• 52-Week Range: $2.20 to $5.27
• Volume: 83,546 shs
• Average Volume: 27,375 shs
• Market Capitalization: $6.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Xenetic Biosciences Stock Analysis - MarketRank™

Xenetic Biosciences scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Xenetic Biosciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Xenetic Biosciences are expected to grow in the coming year, from ($1.01) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xenetic Biosciences is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xenetic Biosciences is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xenetic Biosciences has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.28% of the float of Xenetic Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Xenetic Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xenetic Biosciences does not currently pay a dividend.

Dividend Growth

Xenetic Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.28% of the float of Xenetic Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Xenetic Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Xenetic Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

Search Interest

2 people have searched for XBIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.70% of the stock of Xenetic Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.12% of the stock of Xenetic Biosciences is held by institutions.

XBIO Stock Analysis - Frequently Asked Questions

How have XBIO shares performed this year?

Xenetic Biosciences' stock was trading at $3.99 on January 1st, 2025. Since then, XBIO shares have decreased by 1.3% and is now trading at $3.94.
View the best growth stocks for 2025 here.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences, Inc. (NASDAQ:XBIO) released its earnings results on Tuesday, May, 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.13. The firm had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.52 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 57.31% and a negative net margin of 142.10%.

When did Xenetic Biosciences' stock split?

Xenetic Biosciences's stock reverse split before market open on Monday, May 15th 2023.The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenetic Biosciences investors own include FuelCell Energy (FCEL), OPKO Health (OPK), VBI Vaccines (VBIV), Bionano Genomics (BNGO), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:XBIO
• CIK: 1534525
• Web: www.xeneticbio.com
• Phone: 781-778-7720
• Fax: N/A
• Employees: 4
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($2.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.96 million
• Net Margins: -142.10%
• Pretax Margin: -142.06%
• Return on Equity: -57.31%
• Return on Assets: -49.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.20
• Quick Ratio: 8.20

Sales & Book Value

• Annual Sales: $2.50 million
• Price / Sales: 2.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.89 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 1,540,000
• Free Float: 1,315,000
• Market Cap: $6.07 million
• Optionable: Not Optionable
• Beta: 2.34